Even though regulatory bodies like the EMA and FDA cannot work in tandem with industry and academia, they do share a common goal: to develop and launch new drugs that improve society's wellbeing.

TI Pharma brings all stakeholders to the same table. It acts as a neutral platform where common ground can be created and conflicting interests can be mediated, jointly working towards an improved and innovation-friendly regulatory framework.

“Running public-private partnerships is a profession by itself. TI Pharma is an excellent example of how you can do this in an effective way.”

Hugo Hurts
Director/Secretary of the Medicines Evaluation Board

Hugo Hurts
Director/Secretary of the Medicines Evaluation Board

Share this page: